Last reviewed · How we verify
DCCR
DCCR is a small molecule that inhibits the activity of the CDK8 protein.
DCCR is a small molecule that inhibits the activity of the CDK8 protein. Used for Solid tumors with high CDK8 expression.
At a glance
| Generic name | DCCR |
|---|---|
| Also known as | Diazoxide Choline Controlled-Release Tablet |
| Sponsor | Essentialis, Inc. |
| Drug class | CDK8 inhibitor |
| Target | CDK8 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CDK8 is a component of the Mediator complex, which plays a key role in regulating gene transcription. By inhibiting CDK8, DCCR aims to modulate the expression of genes involved in various diseases.
Approved indications
- Solid tumors with high CDK8 expression
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
- Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome (PHASE3)
- Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period (PHASE3)
- A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome (PHASE3)
- An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities (PHASE2)
- An Open-Label Study of DCCR Tablet in Patients With PWS (PHASE3)
- A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) (PHASE2)
- Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DCCR CI brief — competitive landscape report
- DCCR updates RSS · CI watch RSS
- Essentialis, Inc. portfolio CI